Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 921

1.

FTBMT, a Novel and Selective GPR52 Agonist, Demonstrates Antipsychotic-Like and Procognitive Effects in Rodents, Revealing a Potential Therapeutic Agent for Schizophrenia.

Nishiyama K, Suzuki H, Harasawa T, Suzuki N, Kurimoto E, Kawai T, Maruyama M, Komatsu H, Sakuma K, Shimizu Y, Shimojo M.

J Pharmacol Exp Ther. 2017 Nov;363(2):253-264. doi: 10.1124/jpet.117.242925. Epub 2017 Aug 29.

PMID:
28851764
2.

Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial.

Larsen JR, Vedtofte L, Jakobsen MSL, Jespersen HR, Jakobsen MI, Svensson CK, Koyuncu K, Schjerning O, Oturai PS, Kjaer A, Nielsen J, Holst JJ, Ekstrøm CT, Correll CU, Vilsbøll T, Fink-Jensen A.

JAMA Psychiatry. 2017 Jul 1;74(7):719-728. doi: 10.1001/jamapsychiatry.2017.1220.

PMID:
28601891
3.

Allosteric Modulation of GPCRs: New Insights and Potential Utility for Treatment of Schizophrenia and Other CNS Disorders.

Foster DJ, Conn PJ.

Neuron. 2017 May 3;94(3):431-446. doi: 10.1016/j.neuron.2017.03.016. Review.

PMID:
28472649
4.

RP5063, an atypical antipsychotic drug with a unique pharmacologic profile, improves declarative memory and psychosis in mouse models of schizophrenia.

Rajagopal L, Kwon S, Huang M, Michael E, Bhat L, Cantillon M, Meltzer HY.

Behav Brain Res. 2017 Aug 14;332:180-199. doi: 10.1016/j.bbr.2017.02.036. Epub 2017 Mar 31.

PMID:
28373127
5.

Dopamine D<sub>4</sub> receptor stimulation contributes to novel object recognition: Relevance to cognitive impairment in schizophrenia.

Miyauchi M, Neugebauer NM, Meltzer HY.

J Psychopharmacol. 2017 Apr;31(4):442-452. doi: 10.1177/0269881117693746. Epub 2017 Feb 1.

PMID:
28347261
6.

A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment.

Palacios JM, Pazos A, Hoyer D.

Psychopharmacology (Berl). 2017 May;234(9-10):1395-1418. doi: 10.1007/s00213-017-4545-5. Epub 2017 Mar 7. Review.

PMID:
28265714
7.

Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure.

Möller D, Banerjee A, Uzuneser TC, Skultety M, Huth T, Plouffe B, Hübner H, Alzheimer C, Friedland K, Müller CP, Bouvier M, Gmeiner P.

J Med Chem. 2017 Apr 13;60(7):2908-2929. doi: 10.1021/acs.jmedchem.6b01857. Epub 2017 Mar 22.

PMID:
28248104
8.

Brexpiprazole.

Markovic M, Gallipani A, Patel KH, Maroney M.

Ann Pharmacother. 2017 Apr;51(4):315-322. doi: 10.1177/1060028016678262. Epub 2016 Dec 15. Review.

PMID:
28228056
9.

Atypical antipsychotic clozapine reversed deficit on prepulse inhibition of the acoustic startle reflex produced by microinjection of DOI into the inferior colliculus in rats.

de Oliveira RP, Nagaishi KY, Barbosa Silva RC.

Behav Brain Res. 2017 May 15;325(Pt A):72-78. doi: 10.1016/j.bbr.2017.01.053. Epub 2017 Feb 12.

PMID:
28202410
10.

The group II metabotropic glutamate receptor agonist LY354740 and the D2 receptor antagonist haloperidol reduce locomotor hyperactivity but fail to rescue spatial working memory in GluA1 knockout mice.

Boerner T, Bygrave AM, Chen J, Fernando A, Jackson S, Barkus C, Sprengel R, Seeburg PH, Harrison PJ, Gilmour G, Bannerman DM, Sanderson DJ.

Eur J Neurosci. 2017 Apr;45(7):912-921. doi: 10.1111/ejn.13539. Epub 2017 Mar 4.

11.

Dissociable effects of the d- and l- enantiomers of govadine on the disruption of prepulse inhibition by MK-801 and apomorphine in male Long-Evans rats.

Lins BR, Marks WN, Phillips AG, Howland JG.

Psychopharmacology (Berl). 2017 Apr;234(7):1079-1091. doi: 10.1007/s00213-017-4540-x. Epub 2017 Feb 8.

PMID:
28180960
12.

Differential effects of antipsychotic and propsychotic drugs on prepulse inhibition and locomotor activity in Roman high- (RHA) and low-avoidance (RLA) rats.

Oliveras I, Sánchez-González A, Sampedro-Viana D, Piludu MA, Río-Alamos C, Giorgi O, Corda MG, Aznar S, González-Maeso J, Gerbolés C, Blázquez G, Cañete T, Tobeña A, Fernández-Teruel A.

Psychopharmacology (Berl). 2017 Mar;234(6):957-975. doi: 10.1007/s00213-017-4534-8. Epub 2017 Feb 2.

PMID:
28154892
13.

Emerging pharmacological therapies in schizophrenia: what's new, what's different, what's next?

Citrome L.

CNS Spectr. 2016 Dec;21(S1):1-12. doi: 10.1017/S1092852916000729. Review.

PMID:
28044942
14.

5-HT1A C-1019G (rs6295) Predicts Aripiprazole Treatment Response Specifically for Cognitive and Depressive Symptoms in Schizophrenia.

Chen SF, Shen YC.

J Clin Psychopharmacol. 2017 Feb;37(1):114-118. doi: 10.1097/JCP.0000000000000628. No abstract available.

PMID:
28027114
15.

Brexpiprazole for the treatment of schizophrenia.

Hsu WY, Lane HY, Lin CH.

Expert Opin Pharmacother. 2017 Feb;18(2):217-223. doi: 10.1080/14656566.2016.1274972. Epub 2017 Jan 16. Review.

PMID:
27997809
16.

New Concepts in Dopamine D<sub>2</sub> Receptor Biased Signaling and Implications for Schizophrenia Therapy.

Urs NM, Peterson SM, Caron MG.

Biol Psychiatry. 2017 Jan 1;81(1):78-85. doi: 10.1016/j.biopsych.2016.10.011. Epub 2016 Oct 19. Review.

17.

3-Furan-2-yl-N-p-tolyl-acrylamide, a positive allosteric modulator of the α7 nicotinic receptor, reverses schizophrenia-like cognitive and social deficits in rats.

Potasiewicz A, Hołuj M, Kos T, Popik P, Arias HR, Nikiforuk A.

Neuropharmacology. 2017 Feb;113(Pt A):188-197. doi: 10.1016/j.neuropharm.2016.10.002. Epub 2016 Oct 4.

PMID:
27717880
18.

Asenapine reduces anxiety-related behaviours in rat conditioned fear stress model.

Ohyama M, Kondo M, Yamauchi M, Imanishi T, Koyama T.

Acta Neuropsychiatr. 2016 Dec;28(6):327-336. Epub 2016 Apr 21.

PMID:
27099073
19.

Striatal cholinergic interneurons and D2 receptor-expressing GABAergic medium spiny neurons regulate tardive dyskinesia.

Bordia T, Zhang D, Perez XA, Quik M.

Exp Neurol. 2016 Dec;286:32-39. doi: 10.1016/j.expneurol.2016.09.009. Epub 2016 Sep 19.

20.

[The kynurenic acid hypothesis - a new look at etiopathogenesis and treatment of schizophrenia].

Flis M, Szymona K, Morylowska-Topolska J, Urbańska A, Krukow P, Kandefer-Szerszeń M, Zdzisińska B, Urbańska EM, Karakuła-Juchnowicz H.

Pol Merkur Lekarski. 2016 Sep 29;41(243):160-164. Review. Polish.

PMID:
27755520

Supplemental Content

Loading ...
Support Center